Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Inhibición del ligando RANK para combatir la sarcopenia con osteoporosis subyacente

15 de septiembre de 2026 actualizado por: Ronald Man Yeung WONG, Prince of Wales Hospital, Shatin, Hong Kong

Inhibición del ligando RANK para combatir la sarcopenia con osteoporosis subyacente: un ensayo aleatorizado, doble ciego, doble simulación y controlado de forma activa

The objective of this study was to conduct a randomized, double-blind, double-dummy active controlled trial to determine the efficacy of denosumab in treating sarcopenia with underlying osteoporosis.

Descripción general del estudio

Estado

Reclutamiento

Descripción detallada

Aims:

  1. To assess whether receptor activator of nuclear factor-kB ligand (RANKL)-inhibition can treat sarcopenia in osteosarcopenic patients, in terms of appendicular skeletal muscle mass (ASM), handgrip strength, and physical performance.
  2. To assess whether RANKL-inhibition improves quality of life, and decreases falls, fractures, hospital admissions and mortality in osteosarcopenic patients.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

120

Fase

  • Fase 4

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

      • Hong Kong, Porcelana
        • Reclutamiento
        • The Chinese University of Hong Kong
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

65 años y mayores (Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Elderly males or females aged 65 years or older
  • diagnosed with osteosarcopenia (sarcopenia diagnosis based on AWGS 2019 guidelines - low appendicular skeletal muscle mass (ASM) by Dual-energy X-ray absorptiometry (DXA) (M:<7.0kg/m2, F:<5.4kg/m2) AND low handgrip strength (M:<28kg, F:<18kg) OR low physical performance (6-metre walk: <1.0m/s or 5-time chair stand test ≥ 12 s); osteoporosis diagnosed based on World Health Organization (WHO) criteria with DXA scan T-score ≤ -2.5)
  • Willing and able to comply with study protocol including follow-up evaluations.

Exclusion Criteria:

  • history of recent fracture i.e., within 3 months
  • history of prior anti-osteoporotic drug
  • disease or medication affecting bone or muscle metabolism
  • Chairbound or bedbound
  • Unable to agree for consent
  • contraindication to drug i.e., Denosumab or Zoledronic Acid
  • Underlying malignancy or disease known to cause cachexia
  • severe renal impairment e.g., Creatinine Clearance (CrCl) < 35ml/min
  • moderate to severe liver failure (Child-Pugh Class B or C).

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Triple

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: Denosumab group

60mg subcutaneous Denosumab (1mL solution) every 6 months and intravenous placebo (100mL normal saline) once yearly

60mg subcutaneous Denosumab (1mL solution) every 6 months and intravenous placebo (100mL normal saline) once yearly

Comparador de placebos: Zolendronic acid group

5mg intravenous Zoledronic Acid (100mL solution) once yearly and subcutaneous placebo (1mL normal saline) every 6 months

5mg intravenous Zoledronic Acid (100mL solution) once yearly and subcutaneous placebo (1mL normal saline) every 6 months

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
6-metre walk
Periodo de tiempo: From enrollment to the end of treatment at 52 weeks

The time taken to walk 6 metres without deceleration. Average result of 2 trials is recorded. Slow speed is defined as <1.0m/s.

From enrollment to the end of treatment at 52 weeks
5-time chair stand test
Periodo de tiempo: From enrollment to the end of treatment at 8 weeks

The time to rise from a chair 5 times is recorded. The cut-off for is taken at >=12 seconds.

From enrollment to the end of treatment at 8 weeks
Appendicular skeletal muscle mass (ASM)
Periodo de tiempo: From enrollment to the end of treatment at 52 weeks

Determined with Dual-energy X-ray absorptiometry (Horizon®, DXA system, Hologic, USA). Total ASM by DXA is evaluated by segmented measurement of muscle mass at four limbs by operator-defined cutlines at specific anatomical landmarks. ASM is adjusted to square of height to calculate ASMI (kg/m2). Low ASMI by DXA is < 7 kg/m2 for men and 5.4 kg/m2 for women.

From enrollment to the end of treatment at 52 weeks
Handgrip strength
Periodo de tiempo: From enrollment to the end of treatment at 52 weeks

Assessed by spring-type hand dynamometer (JAMAR Hand Dynamometer 5030JO). Cut-off for men is < 28kg, and female is <18kg. Maximum reading of 3 trials using dominant hand in a maximum-effort isometric contraction

From enrollment to the end of treatment at 52 weeks
Quadriceps muscle strength
Periodo de tiempo: From enrollment to the end of treatment at 52 weeks

Measured on affected limb with isometric dynamometer (Baseline, Genova, Italy). Subject will sit on a chair with both feet above ground, while raising the affected leg 45° forwards. The dynamometer is placed above the ankle and the subject will push the leg forward with maximum force. Measurements will be repeated 3 times and maximum value will be used for evaluation

From enrollment to the end of treatment at 52 weeks
Balancing ability
Periodo de tiempo: From enrollment to the end of treatment at 52 weeks

The Basic Balance Master System (NeuroCom International Inc, USA) is used to measure static and dynamic ability of subjects to maintain center of balance. Subjects will stand barefoot on force plate and control location of their center-of-gravity by weight-shifting to eight different targets. Measured parameters of limits of stability test includes directional control (%).

From enrollment to the end of treatment at 52 weeks
Balancing ability
Periodo de tiempo: From enrollment to the end of treatment at 52 weeks

The Basic Balance Master System (NeuroCom International Inc, USA) is used to measure static and dynamic ability of subjects to maintain center of balance. Subjects will stand barefoot on force plate and control location of their center-of-gravity by weight-shifting to eight different targets. Measured parameters of limits of stability test includes movement velocity (degrees/s)

From enrollment to the end of treatment at 52 weeks
Balancing ability
Periodo de tiempo: From enrollment to the end of treatment at 52 weeks

The Basic Balance Master System (NeuroCom International Inc, USA) is used to measure static and dynamic ability of subjects to maintain center of balance. Subjects will stand barefoot on force plate and control location of their center-of-gravity by weight-shifting to eight different targets. Measured parameters of limits of stability test includes endpoint excursion (%)

From enrollment to the end of treatment at 52 weeks
Balancing ability
Periodo de tiempo: From enrollment to the end of treatment at 52 weeks

The Basic Balance Master System (NeuroCom International Inc, USA) is used to measure static and dynamic ability of subjects to maintain center of balance. Subjects will stand barefoot on force plate and control location of their center-of-gravity by weight-shifting to eight different targets. Measured parameters of limits of stability test includes maximum excursion (%)

From enrollment to the end of treatment at 52 weeks
Balancing ability
Periodo de tiempo: From enrollment to the end of treatment at 52 weeks

The Basic Balance Master System (NeuroCom International Inc, USA) is used to measure static and dynamic ability of subjects to maintain center of balance. Subjects will stand barefoot on force plate and control location of their center-of-gravity by weight-shifting to eight different targets. Measured parameters of limits of stability test includes reaction time(s)

From enrollment to the end of treatment at 52 weeks

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Falls
Periodo de tiempo: From enrollment to the end of treatment at 52 weeks

To assess the occurrence of falls, patients are required to self-report via a fall calendar, which will be returned at 1-year

From enrollment to the end of treatment at 52 weeks
Fracture
Periodo de tiempo: From enrollment to the end of treatment at 52 weeks

Assess occurrence of a fracture within a year of study period.

From enrollment to the end of treatment at 52 weeks
Quality of life Short Form-36 (SF-36)
Periodo de tiempo: From enrollment to the end of treatment at 52 weeks

The highest score is 900, and the lowest score is 0. Highest score indicates a better quality of life.

From enrollment to the end of treatment at 52 weeks
Physical activity scale for elderly (PASE)
Periodo de tiempo: From enrollment to the end of treatment at 52 weeks

It assesses the types of activities typically chosen by older adults, ranging from 0 to 793, with higher scores indicating greater physical activity

From enrollment to the end of treatment at 52 weeks
Food frequency questionnaire
Periodo de tiempo: From enrollment to the end of treatment at 52 weeks

Daily and weekly intake of 280 food items will be performed using a validated food frequency questionnaire developed in a local population survey. Mean nutrient quantitation and energy intake per day will be calculated referring to food composition tables derived from the Chinese Medical Sciences Institute and Centre for Food Safety in Hong Kong.

From enrollment to the end of treatment at 52 weeks
Hospital admissions
Periodo de tiempo: From enrollment to the end of treatment at 52 weeks

Number and cause of emergency hospital admission within 1 year of study period are documented.

From enrollment to the end of treatment at 52 weeks
Mortality
Periodo de tiempo: From enrollment to the end of treatment at 52 weeks

Mortality within 1-year of study period is documented.

From enrollment to the end of treatment at 52 weeks

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

9 de abril de 2024

Finalización primaria (Estimado)

1 de abril de 2027

Finalización del estudio (Estimado)

1 de octubre de 2027

Fechas de registro del estudio

Enviado por primera vez

15 de septiembre de 2024

Primero enviado que cumplió con los criterios de control de calidad

13 de octubre de 2024

Publicado por primera vez (Actual)

16 de octubre de 2024

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

18 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

15 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

Sí

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir